Transcriptomic intratumor heterogeneity of breast cancer patient-derived organoids may reflect the unique biological features of the tumor of origin

被引：0
作者：
Sumito Saeki
Kohei Kumegawa
Yoko Takahashi
Liying  Yang
Tomo Osako
Mahmut Yasen
Kazutaka Otsuji
Kenichi Miyata
Kaoru Yamakawa
Jun Suzuka
Yuri Sakimoto
Yukinori Ozaki
Toshimi Takano
Takeshi Sano
Tetsuo Noda
Shinji Ohno
Ryoji Yao
Takayuki Ueno
Reo Maruyama
机构：
[1] Japanese Foundation for Cancer Research,Project for Cancer Epigenomics, Cancer Institute
[2] Japanese Foundation for Cancer Research,Breast Surgical Oncology, Breast Oncology Center, Cancer Institute Hospital
[3] Japanese Foundation for Cancer Research,Cancer Cell Diversity Project, NEXT
[4] Japanese Foundation for Cancer Research,Ganken Program
[5] Japanese Foundation for Cancer Research,Division of Pathology, Cancer Institute
[6] Japanese Foundation for Cancer Research,Cancer Informatics and Biobanking Platform Project, NEXT
[7] Japanese Foundation for Cancer Research,Ganken Program
[8] Japanese Foundation for Cancer Research,Breast Medical Oncology, Breast Oncology Center, Cancer Institute Hospital
[9] Japanese Foundation for Cancer Research,Department of Gastroenterological Surgery, Gastroenterological Center, Cancer Institute Hospital
[10] Japanese Foundation for Cancer Research,Director’s Room, Cancer Institute
来源：
Breast Cancer Research | / 25卷
关键词：
Intratumor heterogeneity; Breast cancer; Patient-derived organoids; scRNA-seq; Cancer cell diversity; Inflammatory breast cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 207 条
  • [1] McGranahan N(2017)Clonal heterogeneity and tumor evolution: past, present, and the future Cell 168 613-628
  • [2] Swanton C(2022)Untangling the web of intratumour heterogeneity Nat Cell Biol 24 1192-1201
  • [3] Li Z(2018)Intratumor heterogeneity of the estrogen receptor and the long-term risk of fatal breast cancer J Natl Cancer Inst 110 726-733
  • [4] Seehawer M(2021)Predictive significance of HER2 intratumoral heterogeneity, determined by simultaneous gene and protein analysis, for resistance to trastuzumab-based treatments for HER2-positive breast cancer Virchows Arch 479 13-21
  • [5] Polyak K(2021)Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab Cancer Discov 11 2474-2487
  • [6] Lindström LS(2020)Human organoids: model systems for human biology and medicine Nat Rev Mol Cell Biol 21 571-584
  • [7] Yau C(2019)Cancer modeling meets human organoid technology Science 364 952-955
  • [8] Czene K(2018)A living biobank of breast cancer organoids captures disease heterogeneity Cell 172 373-386e310
  • [9] Thompson CK(2018)A comprehensive human gastric cancer organoid biobank captures tumor subtype heterogeneity and enables therapeutic screening Cell Stem Cell 23 882-897811
  • [10] Hoadley KA(2022)Occult polyclonality of preclinical pancreatic cancer models drives in vitro evolution Nat Commun 13 3652-967
12345678910